Bone marrow transplantation improves hepatic fibrosis in Abcb4 -/- mice via Th1 response and matrix metalloproteinase activity

Gut

Volumn 61, Issue 6, 2012, Pages 907-916

  Roderfeld, Martin ^a   Rath, Timo ^a   Pasupuleti, Sravanthi ^a   Zimmermann, Marc ^a   Neumann, Caterina ^a   Churin, Yuri ^a   Dierkes, Christian ^b   Voswinckel, Robert ^a   Barth, Peter J ^b   Zahner, Daniel ^a   Graf, Jürgen ^c,d   Roeb, Elke ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c Deutsche Lufthansa AG   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; CHEMOKINE RECEPTOR; COLLAGENASE 3; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 13; MATRILYSIN; MATRIX METALLOPROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; GENE EXPRESSION; GRANULOCYTE; IMMUNOMODULATION; LIVER FIBROSIS; LIVER REGENERATION; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; BONE MARROW TRANSPLANTATION; CHEMOKINES; CYTOKINES; INTERFERON-GAMMA; LIVER; LIVER CIRRHOSIS; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; P-GLYCOPROTEINS; TH1 CELLS;

EID: 84860586403     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300608     Document Type: Article

References (75)

1. Higashiyama R, Moro T, Nakao S, et al. Negligible contribution of bone marrow-derived cells to collagen production during hepatic fibrogenesis in mice. Gastroenterology 2009;137:1459-66.
2. Kallis YN, Forbes SJ. The bone marrow and liver fibrosis: friend or foe? Gastroenterology 2009;137:1218-21.
3. Fang B, Shi M, Liao L, et al. Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation 2004;78:83-8.
4. Harb R, Xie G, Lutzko C, et al. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury. Gastroenterology 2009;137:704-12.
5. Nakamura T, Torimura T, Sakamoto M, et al. Significance and therapeutic potential of endothelial progenitor cell transplantation in a cirrhotic liver rat model. Gastroenterology 2007;133:91-107.
6. Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004;40:1304-11. (Pubitemid 39657004)
7. am Esch JS, Knoefel WT, Klein M, et al. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 2005;23:463-70.
8. Terai S, Ishikawa T, Omori K, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 2006;24:2292-8. (Pubitemid 44527483)
9. Kisseleva T, Uchinami H, Feirt N, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006;45:429-38. (Pubitemid 44142115)
10. Forbes SJ, Russo FP, Rey V, et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004;126:955-63. (Pubitemid 38451166)
11. Russo FP, Alison MR, Bigger BW, et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006;130:1807-21. (Pubitemid 43668827)
12. Miyata E, Masuya M, Yoshida S, et al. Hematopoietic origin of hepatic stellate cells in the adult liver. Blood 2008;111:2427-35. (Pubitemid 351451456)
13. -/- mice. Hepatology 2010;51:267-76.
14. Henkel C, Roderfeld M, Weiskirchen R, et al. Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis. Proteomics 2006;6:6538-48. (Pubitemid 46048392)
15. Okabe M, Ikawa M, Kominami K, et al. 'Green mice' as a source of ubiquitous green cells. FEBS Lett 1997;407:313-19. (Pubitemid 27199450)
16. Voswinckel R, Ziegelhoeffer T, Heil M, et al. Circulating vascular progenitor cells do not contribute to compensatory lung growth. Circ Res 2003;93:372-9. (Pubitemid 37048250)
17. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409-17.
18. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
19. Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981;112:70-5.
20. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:2002-7.
21. Roeb E, Behrmann I, Grotzinger J, et al. An MMP-9 mutant without gelatinolytic activity as a novel TIMP-1-antagonist. FASEB J 2000;14:1671-3.
22. Higashiyama R, Inagaki Y, Hong YY, et al. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. Hepatology 2007;45:213-22. (Pubitemid 46144381)
23. Baba S, Fujii H, Hirose T, et al. Commitment of bone marrow cells to hepatic stellate cells in mouse. J Hepatol 2004;40:255-60. (Pubitemid 38115830)
24. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004;4:583-94.
25. Borg BB, Seetharam A, Subramanian V, et al. Immune response to extracellular matrix collagen in chronic hepatitis C-induced liver fibrosis. Liver Transpl 2011;17:814-23.
26. Coutinho HM, Acosta LP, Wu HW, et al. Th2 cytokines are associated with persistent hepatic fibrosis in human Schistosoma japonicum infection. J Infect Dis 2007;195:288-95.
27. Reiman RM, Thompson RW, Feng CG, et al. Interleukin-5 (IL-5) augments the progression of liver fibrosis by regulating IL-13 activity. Infect Immun 2006;74:1471-9. (Pubitemid 43346779)
28. Gao B, Radaeva S, Jeong WI. Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis. Expert Rev Gastroenterol Hepatol 2007;1:173-80.
29. Ha MH, Wei L, Rao HY, et al. Effect of interferon-gamma on hepatic stellate cells stimulated by acetaldehyde. Hepatogastroenterology 2008;55:1059-65. (Pubitemid 351975985)
30. Wynn TA, Cheever AW, Jankovic D, et al. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 1995;376:594-6.
31. Yao H, Pan J, Qian Y, et al. Enhanced effect of soluble transforming growth factorbeta receptor II and IFN-gamma fusion protein in reversing hepatic fibrosis. Eur J Med Res 2010;15:152-61.
32. Shao DD, Suresh R, Vakil V, et al. Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 2008;83:1323-33. (Pubitemid 351960310)
33. Saile B, Eisenbach C, Dudas J, et al. Interferon-gamma acts proapoptotic on hepatic stellate cells (HSC) and abrogates the antiapoptotic effect of interferon-alpha by an HSP70-dependant pathway. Eur J Cell Biol 2004;83:469-76. (Pubitemid 39439959)
34. Popov Y, Patsenker E, Fickert P, et al. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 2005;43:1045-54. (Pubitemid 41627991)
35. Booth M, Mwatha JK, Joseph S, et al. Periportal fibrosis in human Schistosoma mansoni infection is associated with low IL-10, low IFN-gamma, high TNF-alpha, or low RANTES, depending on age and gender. J Immunol 2004;172:1295-303. (Pubitemid 38113793)
36. Herbert DR, Orekov T, Perkins C, et al. IL-10 and TGF-beta redundantly protect against severe liver injury and mortality during acute schistosomiasis. J Immunol 2008;181:7214-20.
37. Louis H, Van Laethem JL, Wu W, et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology 1998;28:1607-15. (Pubitemid 28549131)
38. Louis H, Le MA, Quertinmont E, et al. Repeated concanavalin A challenge in mice induces an interleukin 10-producing phenotype and liver fibrosis. Hepatology 2000;31:381-90. (Pubitemid 30078603)
39. Louis H, Le MO, Goldman M, et al. Modulation of liver injury by interleukin-10. Acta Gastroenterol Belg 2003;66:7-14. (Pubitemid 36307052)
40. Tang-Feldman YJ, Lochhead GR, Lochhead SR, et al. Interleukin-10 repletion suppresses pro-inflammatory cytokines and decreases liver pathology without altering viral replication in murine cytomegalovirus (MCMV)-infected IL-10 knockout mice. Inflamm Res 2011;60:233-43.
41. Thompson K, Maltby J, Fallowfield J, et al. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology 1998;28:1597-606. (Pubitemid 28549130)
42. Yin S, Wang H, Park O, et al. Enhanced liver regeneration in IL-10-deficient mice after partial hepatectomy via stimulating inflammatory response and activating hepatocyte STAT3. Am J Pathol 2011;178:1614-21.
43. Hoffmann KF, Cheever AW, Wynn TA. IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol 2000;164:6406-16. (Pubitemid 30408823)
44. Vaillant B, Chiaramonte MG, Cheever AW, et al. Regulation of hepatic fibrosis and extracellular matrix genes by the th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol 2001;167:7017-26. (Pubitemid 33144197)
45. Krohn N, Kapoor S, Enami Y, et al. Hepatocyte transplantation-induced liver inflammation is driven by cytokines-chemokines associated with neutrophils and Kupffer cells. Gastroenterology 2009;136:1806-17.
46. Li X, Klintman D, Liu Q, et al. Critical role of CXC chemokines in endotoxemic liver injury in mice. J Leukoc Biol 2004;75:443-52. (Pubitemid 38316375)
47. Moreno C, Gustot T, Nicaise C, et al. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology 2005;42:854-62. (Pubitemid 41401123)
48. Gaga M, Ong YE, Benyahia F, et al. Skin reactivity and local cell recruitment in human atopic and nonatopic subjects by CCL2/MCP-1 and CCL3/MIP-1alpha. Allergy 2008;63:703-11. (Pubitemid 351591843)
49. Rittner HL, Mousa SA, Labuz D, et al. Selective local PMN recruitment by CXCL1 or CXCL2/3 injection does not cause inflammatory pain. J Leukoc Biol 2006;79:1022-32. (Pubitemid 44835589)
50. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007;25:787-820. (Pubitemid 46697924)
51. Wilsson A, Lind S, Ohman L, et al. Apoptotic neutrophils containing Staphylococcus epidermidis stimulate macrophages to release the proinflammatory cytokines tumor necrosis factor-alpha and interleukin-6. FEMS Immunol Med Microbiol 2008;53:126-35. (Pubitemid 351659717)
52. Liu LY, Bates ME, Jarjour NN, et al. Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-alpha. J Immunol 2007;179:4840-8.
53. Saile B, Matthes N, Knittel T, et al. Transforming growth factor beta and tumor necrosis factor alpha inhibit both apoptosis and proliferation of activated rat hepatic stellate cells. Hepatology 1999;30:196-202. (Pubitemid 29300586)
54. Connolly MK, Bedrosian AS, Mallen-St CJ, et al. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest 2009;119:3213-25.
55. Ingaramo PI, Ronco MT, Frances DE, et al. Tumor necrosis factor alpha pathways develops liver apoptosis in type 1 diabetes mellitus. Mol Immunol 2011;48:1397-407.
56. Bachem MG, Riess U, Gressner AM. Liver fat storing cell proliferation is stimulated by epidermal growth factor/transforming growth factor alpha and inhibited by transforming growth factor beta. Biochem Biophys Res Commun 1989;162:708-14. (Pubitemid 19200897)
57. Badley AD, Dockrell D, Simpson M, et al. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med 1997;185:55-64. (Pubitemid 27039440)
58. Davis BH. Transforming growth factor beta responsiveness is modulated by the extracellular collagen matrix during hepatic ito cell culture. J Cell Physiol 1988;136:547-53.
59. Davis BH, Rapp UR, Davidson NO. Retinoic acid and transforming growth factor beta differentially inhibit platelet-derived-growth-factor-induced Ito-cell activation. Biochem J 1991;278:43-7.
60. Knittel T, Muller L, Saile B, et al. Effect of tumour necrosis factor-alpha on proliferation, activation and protein synthesis of rat hepatic stellate cells. J Hepatol 1997;27:1067-80. (Pubitemid 27523966)
61. Meyer DH, Bachem MG, Gressner AM. Bidirectional effects of Kupffer cells on hepatocyte proliferation in vitro. FEBS Lett 1991;283:150-4.
62. Pinzani M, Gesualdo L, Sabbah GM, et al. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest 1989;84:1786-93. (Pubitemid 20016182)
63. Yoshida Y, Hirano T, Son G, et al. Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease. Am J Physiol Gastrointest Liver Physiol 2007;293:1114-23.
64. Ichiki Y, Bowlus CL, Shimoda S, et al. T cell immunity and graft-versus-host disease (GVHD). Autoimmun Rev 2006;5:1-9. (Pubitemid 41759436)
65. Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood 2005;105:4200-6. (Pubitemid 40720763)
66. Chiba T, Yokosuka O, Goto S, et al. Clinicopathological features in patients with hepatic graft-versus-host disease. Hepatogastroenterology 2005;52:1849-53. (Pubitemid 41745645)
67. Hidaka M, Iwasaki S, Matsui T, et al. Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2010;45:912-18.
68. Wakae T, Takatsuka H, Seto Y, et al. Similarity between hepatic graft-versus-host disease and primary biliary cirrhosis. Hematology 2002;7:305-10. (Pubitemid 36004365)
69. Serody JS, Burkett SE, Panoskaltsis-Mortari A, et al. T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 2000;96:2973-80.
70. Castor MG, Rezende B, Resende CB, et al. The CCL3/macrophage inflammatory protein-1alpha-binding protein evasin-1 protects from graft-versus-host disease but does not modify graft-versus-leukemia in mice. J Immunol 2010;184:2646-54.
71. Hemmann S, Graf J, Roderfeld M, et al. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007;46:955-75. (Pubitemid 46529049)
72. Roderfeld M, Hemmann S, Roeb E. Mechanisms of fibrinolysis in chronic liver injury (with special emphasis on MMPs and TIMPs). Z Gastroenterol 2007;45:25-33. (Pubitemid 46202718)
73. Knittel T, Mehde M, Kobold D, et al. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol 1999;30:48-60. (Pubitemid 29023652)
74. Yamamoto N, Terai S, Ohata S, et al. A subpopulation of bone marrow cells depleted by a novel antibody, anti-Liv8, is useful for cell therapy to repair damaged liver. Biochem Biophys Res Commun 2004;313:1110-18. (Pubitemid 38050107)
75. Fanning SL, Appel MY, Berger SA, et al. The immunological impact of genetic drift in the B10.BR congenic inbred mouse strain. J Immunol 2009;183:4261-72.